Home > Publications Database > Drug-Related Problems Increase Healthcare Costs for People Living with Dementia. > print

001     145148
005     20240321221031.0
024 7 _ |a 10.3233/JAD-190819
|2 doi
024 7 _ |a pmid:31884468
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
024 7 _ |a altmetric:73652434
|2 altmetric
037 _ _ |a DZNE-2020-00507
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wohlgemuth, Anne
|0 P:(DE-2719)9001143
|b 0
|e First author
|u dzne
245 _ _ |a Drug-Related Problems Increase Healthcare Costs for People Living with Dementia.
260 _ _ |a Amsterdam
|c 2020
|b IOS Press
264 _ 1 |3 print
|2 Crossref
|b IOS Press
|c 2020-01-21
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710934255_2065
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Drug-related problems (DRP) are common in the elderly population, especially in people living with dementia (PwD). DRP are associated with adverse outcomes that could result in increased costs.The objective of the study was to analyze the association between DRP and healthcare costs in PwD.The analysis was based on the cross-sectional data of 424 PwD. Compliance, adverse effects, and drug administration of prescribed and over-the-counter drugs taken were assessed. DRP were identified and classified by pharmacists using an adapted German version of 'PIE-Doc®'. Healthcare utilization was assessed retrospectively used to calculated costs from a public payer perspective using standardized unit costs. The associations between DRP and healthcare costs were analyzed using multiple linear regression models.394 PwD (93%) had at least one DRP. An inappropriate drug choice was significantly associated with increased total costs (b = 2,718€; CI95% 1,448-3,988) due to significantly higher costs for hospitalization (b = 1,936€; 670-3,202) and for medications (b = 417€; 68-765). Problems with medication dosage and drug interactions were significantly associated with higher medication costs (b = 679€; 31-1,328; and b = 630€; 259-1,001, respectively).DRP could significantly lead to adverse outcomes for PwD and healthcare payers, reflected by a higher hospitalization and costs, respectively. Further research is needed to clarify on interventions and approaches efficiently avoiding DRP and on the effect on patient-reported and economic outcomes.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Dementia: economics
|2 MeSH
650 _ 2 |a Drug Interactions
|2 MeSH
650 _ 2 |a Drug-Related Side Effects and Adverse Reactions: economics
|2 MeSH
650 _ 2 |a Drug-Related Side Effects and Adverse Reactions: epidemiology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Germany: epidemiology
|2 MeSH
650 _ 2 |a Health Care Costs: statistics & numerical data
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Nonprescription Drugs
|2 MeSH
650 _ 2 |a Patient Acceptance of Health Care
|2 MeSH
650 _ 2 |a Patient Compliance
|2 MeSH
650 _ 2 |a Pharmacists
|2 MeSH
650 _ 2 |a Prescription Drugs
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Socioeconomic Factors
|2 MeSH
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 1
|u dzne
700 1 _ |a Wucherer, Diana
|0 P:(DE-2719)2810631
|b 2
|u dzne
700 1 _ |a Eichler, Tilly
|0 P:(DE-2719)2810514
|b 3
|u dzne
700 1 _ |a Thyrian, Jochen René
|0 P:(DE-2719)2290613
|b 4
|u dzne
700 1 _ |a Zwingmann, Ina
|0 P:(DE-2719)2811869
|b 5
|u dzne
700 1 _ |a Rädke, Anika
|0 P:(DE-2719)9001134
|b 6
|u dzne
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 7
|e Last author
|u dzne
773 1 8 |a 10.3233/jad-190819
|b : IOS Press, 2020-01-21
|n 2
|p 791-799
|3 journal-article
|2 Crossref
|t Journal of Alzheimer's Disease
|v 73
|y 2020
|x 1387-2877
773 _ _ |a 10.3233/JAD-190819
|g Vol. 73, no. 2, p. 791 - 799
|0 PERI:(DE-600)2070772-1
|n 2
|p 791-799
|t Journal of Alzheimer's disease
|v 73
|y 2020
|x 1387-2877
856 4 _ |u https://pub.dzne.de/record/145148/files/DZNE-2020-00507_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/145148/files/DZNE-2020-00507_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:145148
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001143
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810763
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810631
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2810514
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2290613
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811869
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9001134
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2000040
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky ; AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 0
920 1 _ |0 I:(DE-2719)5000001
|k AG Grabe
|l Biomarkers of Dementia in the General Population
|x 1
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 2
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a I:(DE-2719)5000001
980 _ _ |a I:(DE-2719)1510800
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a UNRESTRICTED
999 C 5 |y 2016
|2 Crossref
|t World Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, quality and costs now and in the future
|o Prince World Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, quality and costs now and in the future 2016
999 C 5 |y 2015
|2 Crossref
|t World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends
|o Prince World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends 2015
999 C 5 |9 -- missing cx lookup --
|a 10.1038/srep42084
|2 Crossref
|o 10.1038/srep42084
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0140-6736(17)33185-9
|2 Crossref
|o 10.1016/S0140-6736(17)33185-9
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0140-6736(05)67889-0
|2 Crossref
|o 10.1016/S0140-6736(05)67889-0
999 C 5 |9 -- missing cx lookup --
|a 10.1136/jnnp.74.9.1206
|2 Crossref
|o 10.1136/jnnp.74.9.1206
999 C 5 |9 -- missing cx lookup --
|a 10.1111/j.1532-5415.2005.00543.x
|2 Crossref
|o 10.1111/j.1532-5415.2005.00543.x
999 C 5 |9 -- missing cx lookup --
|a 10.1186/1471-244X-11-190
|2 Crossref
|o 10.1186/1471-244X-11-190
999 C 5 |9 -- missing cx lookup --
|a 10.1111/j.1365-2125.2006.02744.x
|2 Crossref
|o 10.1111/j.1365-2125.2006.02744.x
999 C 5 |y 2017
|2 Crossref
|t Identification of drug-related problems by means of pharmacy-based medication review – results of a project to optimise medication safety
|o Sell Identification of drug-related problems by means of pharmacy-based medication review – results of a project to optimise medication safety 2017
999 C 5 |9 -- missing cx lookup --
|a 10.1023/A:1019543029936
|2 Crossref
|o 10.1023/A:1019543029936
999 C 5 |9 -- missing cx lookup --
|a 10.1186/s40360-017-0157-2
|2 Crossref
|o 10.1186/s40360-017-0157-2
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.archger.2011.02.005
|2 Crossref
|o 10.1016/j.archger.2011.02.005
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s40801-016-0061-x
|2 Crossref
|o 10.1007/s40801-016-0061-x
999 C 5 |9 -- missing cx lookup --
|a 10.1002/gps.3806
|2 Crossref
|o 10.1002/gps.3806
999 C 5 |9 -- missing cx lookup --
|a 10.1080/13814788.2017.1288211
|2 Crossref
|o 10.1080/13814788.2017.1288211
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S1543-5946(04)90015-3
|2 Crossref
|o 10.1016/S1543-5946(04)90015-3
999 C 5 |9 -- missing cx lookup --
|a 10.1111/j.1365-2125.2009.03419.x
|2 Crossref
|o 10.1111/j.1365-2125.2009.03419.x
999 C 5 |9 -- missing cx lookup --
|a 10.1017/S1041610217001442
|2 Crossref
|o 10.1017/S1041610217001442
999 C 5 |2 Crossref
|o Lyra
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00228-016-2084-3
|2 Crossref
|o 10.1007/s00228-016-2084-3
999 C 5 |9 -- missing cx lookup --
|a 10.1371/journal.pone.0146811
|2 Crossref
|o 10.1371/journal.pone.0146811
999 C 5 |9 -- missing cx lookup --
|a 10.1001/archinte.1997.00440390083011
|2 Crossref
|o 10.1001/archinte.1997.00440390083011
999 C 5 |9 -- missing cx lookup --
|a 10.1186/1745-6215-13-56
|2 Crossref
|o 10.1186/1745-6215-13-56
999 C 5 |9 -- missing cx lookup --
|a 10.1002/gps.1042
|2 Crossref
|o 10.1002/gps.1042
999 C 5 |9 -- missing cx lookup --
|a 10.1136/ebmh.7.3.70
|2 Crossref
|o 10.1136/ebmh.7.3.70
999 C 5 |9 -- missing cx lookup --
|a 10.3233/JAD-151076
|2 Crossref
|o 10.3233/JAD-151076
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0022-3956(75)90026-6
|2 Crossref
|o 10.1016/0022-3956(75)90026-6
999 C 5 |y 2016
|2 Crossref
|o Creavin 2016
999 C 5 |y 2016
|2 Crossref
|t Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie
|o Deuschl Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie 2016
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0022-3956(82)90033-4
|2 Crossref
|o 10.1016/0022-3956(82)90033-4
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0021-9681(87)90171-8
|2 Crossref
|o 10.1016/0021-9681(87)90171-8
999 C 5 |y 2015
|2 Crossref
|o Bock 2015
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s10198-017-0869-7
|2 Crossref
|o 10.1007/s10198-017-0869-7
999 C 5 |9 -- missing cx lookup --
|a 10.1186/1471-2318-13-121
|2 Crossref
|o 10.1186/1471-2318-13-121
999 C 5 |9 -- missing cx lookup --
|a 10.1186/s12877-018-0704-8
|2 Crossref
|o 10.1186/s12877-018-0704-8
999 C 5 |y 2010
|2 Crossref
|o Holt 2010
999 C 5 |9 -- missing cx lookup --
|a 10.2147/CIA.S159966
|2 Crossref
|o 10.2147/CIA.S159966
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s11096-014-0063-2
|2 Crossref
|o 10.1007/s11096-014-0063-2
999 C 5 |9 -- missing cx lookup --
|a 10.3111/13696998.2015.1014090
|2 Crossref
|o 10.3111/13696998.2015.1014090
999 C 5 |9 -- missing cx lookup --
|a 10.1080/17843286.2017.1410606
|2 Crossref
|o 10.1080/17843286.2017.1410606
999 C 5 |2 Crossref
|o
999 C 5 |9 -- missing cx lookup --
|a 10.1186/s12913-016-1366-x
|2 Crossref
|o 10.1186/s12913-016-1366-x
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.pharma.2008.11.003
|2 Crossref
|o 10.1016/j.pharma.2008.11.003
999 C 5 |9 -- missing cx lookup --
|a 10.1248/yakushi.15-00109
|2 Crossref
|o 10.1248/yakushi.15-00109
999 C 5 |y 2008
|2 Crossref
|o Parker 2008
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s40266-017-0505-3
|2 Crossref
|o 10.1007/s40266-017-0505-3
999 C 5 |y 2015
|2 Crossref
|o Reilly 2015

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21